Benitec Biopharma Inc. Operating Cash Flow
Benitec Biopharma Inc. (BNTC) reported Operating Cash Flow of -$16.52 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-09-14
- Benitec Biopharma Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$4.94M.
- Benitec Biopharma Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$4.45M.
- Benitec Biopharma Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$3.78M.
- Benitec Biopharma Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$3.35M.
- Benitec Biopharma Inc. net cash provided by (used in) operating activities for fiscal 2026 was -$16.52M.
- Benitec Biopharma Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$23.59M.
- Benitec Biopharma Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$19.40M.
- Benitec Biopharma Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$18.01M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-14 | -$9.39M derived: sum of 2 quarters · filed 2026-09-14 | -$13.17M derived: sum of 3 quarters · filed 2026-09-14 | -$16.52M 10-K · filed 2026-09-14 |
| 2026-03-31 | -$4.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-14 | -$8.23M derived: sum of 2 quarters · filed 2026-05-14 | -$11.58M 10-Q · filed 2026-05-14 | -$19.79M derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-12-31 | -$3.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | -$7.13M 10-Q · filed 2026-02-12 | -$15.34M derived: sum of 3 quarters · filed 2026-09-14 | -$18.43M derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-09-30 | -$3.35M 10-Q · filed 2025-11-14 | -$11.56M derived: sum of 2 quarters · filed 2026-09-14 | -$14.65M derived: sum of 3 quarters · filed 2026-09-14 | -$22.35M derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-06-30 | -$8.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-14 | -$11.30M derived: sum of 2 quarters · filed 2026-09-14 | -$19.00M derived: sum of 3 quarters · filed 2026-09-14 | -$23.59M 10-K · filed 2026-09-14 |
| 2025-03-31 | -$3.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-14 | -$10.79M derived: sum of 2 quarters · filed 2026-05-14 | -$15.38M 10-Q · filed 2026-05-14 | -$18.67M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$7.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | -$12.29M 10-Q · filed 2026-02-12 | -$15.58M derived: sum of 3 quarters · filed 2026-03-20 | -$21.75M derived: sum of 4 quarters · filed 2026-03-20 |
| 2024-09-30 | -$4.59M 10-Q · filed 2025-11-14 | -$7.88M derived: sum of 2 quarters · filed 2026-03-20 | -$14.05M derived: sum of 3 quarters · filed 2026-03-20 | -$19.41M derived: sum of 4 quarters · filed 2026-03-20 |
| 2024-06-30 | -$3.29M derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-20 | -$9.46M derived: sum of 2 quarters · filed 2026-03-20 | -$14.83M derived: sum of 3 quarters · filed 2026-03-20 | -$19.40M 10-K/A · filed 2026-03-20 |
| 2024-03-31 | -$6.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-14 | -$11.53M derived: sum of 2 quarters · filed 2025-05-14 | -$16.11M 10-Q · filed 2025-05-14 | -$20.20M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$5.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-14 | -$9.94M 10-Q · filed 2025-02-14 | -$14.04M derived: sum of 3 quarters · filed 2025-02-14 | -$18.07M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-09-30 | -$4.58M 10-Q · filed 2024-11-14 | -$8.67M derived: sum of 2 quarters · filed 2024-11-14 | -$12.70M derived: sum of 3 quarters · filed 2024-11-14 | -$18.54M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$4.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-26 | -$8.12M derived: sum of 2 quarters · filed 2024-09-26 | -$13.97M derived: sum of 3 quarters · filed 2024-09-26 | -$18.01M 10-K · filed 2024-09-26 |
| 2023-03-31 | -$4.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-13 | -$9.87M derived: sum of 2 quarters · filed 2024-05-13 | -$13.92M 10-Q · filed 2024-05-13 | -$18.77M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$5.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-13 | -$9.89M 10-Q · filed 2024-02-13 | -$14.74M derived: sum of 3 quarters · filed 2024-02-13 | -$18.16M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | -$4.04M 10-Q · filed 2023-11-13 | -$8.90M derived: sum of 2 quarters · filed 2023-11-13 | -$12.32M derived: sum of 3 quarters · filed 2023-11-13 | -$15.67M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$4.86M derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-21 | -$8.28M derived: sum of 2 quarters · filed 2023-09-21 | -$11.62M derived: sum of 3 quarters · filed 2023-09-21 | -$15.90M 10-K · filed 2023-09-21 |
| 2022-03-31 | -$3.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | -$6.77M derived: sum of 2 quarters · filed 2023-05-15 | -$11.04M 10-Q · filed 2023-05-15 | -$16.20M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$3.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-13 | -$7.62M 10-Q · filed 2023-02-13 | -$12.78M derived: sum of 3 quarters · filed 2023-02-13 | -$14.77M derived: sum of 4 quarters · filed 2023-02-13 |
| 2021-09-30 | -$4.28M 10-Q · filed 2022-11-10 | -$9.44M derived: sum of 2 quarters · filed 2022-11-10 | -$11.42M derived: sum of 3 quarters · filed 2022-11-10 | -$14.75M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$5.16M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-02 | -$7.15M derived: sum of 2 quarters · filed 2022-09-02 | -$10.47M derived: sum of 3 quarters · filed 2022-09-02 | -$12.83M 10-K · filed 2022-09-02 |
| 2021-03-31 | -$1.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-16 | -$5.32M derived: sum of 2 quarters · filed 2022-05-16 | -$7.67M 10-Q · filed 2022-05-16 | -$10.82M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$3.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | -$5.69M 10-Q · filed 2022-02-14 | -$8.83M derived: sum of 3 quarters · filed 2022-02-14 | -$9.60M derived: sum of 4 quarters · filed 2022-02-14 |
| 2020-09-30 | -$2.36M 10-Q · filed 2021-11-15 | -$5.50M derived: sum of 2 quarters · filed 2021-11-15 | -$6.27M derived: sum of 3 quarters · filed 2021-11-15 | -$9.35M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | -$3.15M derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-20 | -$3.91M derived: sum of 2 quarters · filed 2021-09-20 | -$6.99M derived: sum of 3 quarters · filed 2021-09-20 | -$7.54M 10-K · filed 2021-09-20 |
| 2020-03-31 | -$769.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-12 | -$3.85M derived: sum of 2 quarters · filed 2021-05-12 | -$4.39M 10-Q · filed 2021-05-12 | |
| 2019-12-31 | -$3.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-09 | -$3.62M 10-Q · filed 2021-02-09 | ||
| 2019-09-30 | -$545.00K 10-Q · filed 2020-11-13 | |||
| 2019-06-30 | $4.79M 10-K · filed 2020-09-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |